ArticleTranslational cancer research2020
Thymidylate synthase (TS) immunostaining in the diagnosis of the myoepithelial cells, basal cells, stratified epithelium cells, and associated tumors.
Article in Translational cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 0 citations in OpenAlex.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThymidylate synthase (TS) is an important prognostic biomarker for resistance to 5FU-based adjuvant chemotherapy. Recently, we found that TS was specifically expressed in the nucleus of the myoepithelial cell (MEC), basal cell (BC), transitional epithelial cell (TEC), squamous epithelial cell (SEC), and associated tumor using immunostaining. This prompted us to examine whether TS could be used as a diagnostic biomarker for MEC, BC, TEC, SEC, and associated tumors.
methodsFormalin-fixed, paraffin-embedded specimens from 186 cases of tumors were immunostaining for expression of TS and p63. The diagnostic capability of TS as a reliable diagnostic marker was evaluated and compared with the expression of p63.
resultsTS exhibited a strong specific and stable nuclear immunoreactivity in all specimens including MEC, BC, TEC, and SEC when compared with p63. Notably, a variable degree of TS cytoplasmic positive immunoreactivity was observed in 58.3% of squamous-cell carcinoma (SQCC), 37.5% of basal cell carcinoma (BCC), 44.4% transitional-cell carcinomas (TCC), 41.7% mixed tumor (MT) and 56.5% of adenocarcinoma (ADC) specimens.
conclusionsIn addition to being used as a strong prognostic factor for 5-FU resistance, TS also serves as a promising putative diagnostic marker for identifying MEC, BC, SEC, and TEC from GEC, and for distinguishing SQCC, BCC, TCC, and MT from ADC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.